Microarchitectural deterioration of cortical and trabecular bone: Differing effects of denosumab and alendronate
Ego Seeman(The University of Melbourne), José Zanchetta(Universidad del Salvador), Angela M. Cheung(Westat (United States)), Steven K. Boyd(Alberta Bone and Joint Health Institute), Ann E. Kearns(Mayo Clinic), David A. Hanley(The University of Sydney), Sharmila Majumdar(University of California, San Francisco), Elizabeth Shane(Columbia University Irving Medical Center), Deborah E. Sellmeyer(University of California, San Francisco), Thierry Thomas(Lyon 1 Université), Pierre D. Delmas(Inserm), César E. Bogado(Universidad del Salvador), Cesar Libanati(Amgen (United States)), Michelle Fan(National Cancer Centre Japan), Stéphanie Boutroy(Université Claude Bernard Lyon 1)
Cited by 286
Related Papers
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
Functional Disability 5 Years after Acute Respiratory Distress Syndrome
|New England Journal of Medicine|2011|2.8k
Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women
|New England Journal of Medicine|1997|1.6k
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
|Journal of Clinical Oncology|2010|1.6k